Companies seeking regulatory approval for their medical devices in Japan no longer have to submit stability testing data to establish the expiration period of the product unless the technologies are highly-specialised and novel. This move, which is much-welcomed by industry, removes one of the biggest hurdles in Japan's notoriously convoluted regulatory system and is expected to significantly shorten the country's problematic device lag, the delay in approval of new medical devices between Japan and the US/Europe.
Removing the onerous task of stability testing was one of the key objectives of the Regulatory Task Force, a joint...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?